This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Penicillin allergy

Authoring team

Penicillin allergy occurs in 1-10% of patients taking the drug. However life-threatening problems are rare - anaphylaxis occurs in about 15-40/100,000 treated patients. A fatal outcome occurs in about 1.5-2/100,000 treated patients.

Reactions can be divided in four immunological groups:

  • type I reactions - IgE mediated immediate hypersensitivity e.g. urticaria, anaphylactic shock
  • type II reactions - antibody reactions with antigens on cell surfaces e.g. Coomb's positive haemolytic anaemia
  • type III reactions - immune complex mediated e.g. serum sickness, drug-associated fever
  • type IV - delayed cell-mediated reactions e.g. contact dermatitis

A history of allergy does not predispose a patient to the development of penicillin allergy. However if an anphylactic reaction develops in an atopic patient then it is likely to be more severe.

Reference:

  • Drug and Therapeutics Bulletin (1996), 34 (11), 87-88

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.